Details of the Drug Combination

General Information of Drug Combination (ID: DCVRHE9)

• Drug Combination Name: Taxol + RTB101
• Indication: Ewing sarcoma-peripheral primitive neuroectodermal tumour; Status: Investigative [1]
• Component Drugs:
  Taxol (DMUOT9V): Small molecular drug
  RTB101 (DM62QTW): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: ES2
  Zero Interaction Potency (ZIP) Score: 3.25
  Bliss Independence Score: 0.01
  Loewe Additivity Score: 1.55
  LHighest Single Agent (HSA) Score: 4.83

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Taxol

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Approved	[2]
Solid tumour/cancer	2A00-2F9Z	Approved	[3]
Pancreatic cancer	2C10	Phase 3	[4]
Gastric adenocarcinoma	2B72	Phase 2	[5]
Ovarian cancer	2C73	Phase 2	[5]

Taxol Interacts with 2 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Apoptosis regulator Bcl-2 (BCL-2)	TTJGNVC	BCL2_HUMAN	Modulator	[2]
Tubulin beta (TUBB)	TTYFKSZ	NOUNIPROTAC	Modulator	[2]

Indication(s) of RTB101

Disease Entry	ICD 11	Status	REF
Respiratory tract infection	CA45	Phase 3	[6]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2	[7]

RTB101 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
CREB-regulated transcription coactivator 1 (TORC1)	TT4GO0F	CRTC1_HUMAN	Inhibitor	[8]

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Breast carcinoma	DC0T5VG	OCUBM	Investigative	[9]
Colon carcinoma	DC3CIWF	RKO	Investigative	[9]
Invasive ductal carcinoma	DCDNK38	T-47D	Investigative	[9]
Rectal adenocarcinoma	DCTRQ30	SW837	Investigative	[9]
Adenocarcinoma	DCS7NMJ	NCIH520	Investigative	[10]
Adenocarcinoma	DC92RGN	COLO320DM	Investigative	[10]
Adenocarcinoma	DCZV5KI	DLD1	Investigative	[10]
Adenocarcinoma	DCGRRQS	SW-620	Investigative	[10]
Amelanotic melanoma	DCBBQ4W	A2058	Investigative	[10]
Germ cell tumour	DCTTLOL	PA1	Investigative	[10]
Large cell lung carcinoma	DCZSP5I	NCI-H460	Investigative	[10]
Malignant melanoma	DCZNR2C	A375	Investigative	[10]
Malignant melanoma	DCH19U1	HT144	Investigative	[10]
Malignant melanoma	DCZ9I0Z	RPMI7951	Investigative	[10]
Malignant melanoma	DCR11MQ	SKMEL30	Investigative	[10]
Mesothelioma	DCFL9U6	MSTO	Investigative	[10]
Non small cell carcinoma	DCFKD6E	SKMES1	Investigative	[10]
Ovarian endometrioid adenocarcinoma	DCB4T7D	A2780	Investigative	[10]
Ovarian serous cystadenocarcinoma	DC2GCV1	SK-OV-3	Investigative	[10]

References

• [1] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [2] Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009 Sep 1;69(17):6906-14.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] ClinicalTrials.gov (NCT04139915) Effect of RTB101 on Illness Associated With Respiratory Tract Infections in the Elderly. U.S. National Institutes of Health.
• [7] ClinicalTrials.gov (NCT04409327) Phase 2 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes. U.S. National Institutes of Health.
• [8] Anti-ageing pipeline starts to mature.Nat Rev Drug Discov. 2018 Sep;17(9):609-612.
• [9] Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
• [10] Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.